|Mr. Gregory Hamilton||CEO & Member of the Exec. Board||821.42k||N/A||1970|
|Dr. Andrew A. Lukowiak Ph.D.||Pres & Chief Scientific Officer||384.16k||N/A||1972|
|Mr. Jens Ravens||CFO & Member of Exec. Board||N/A||N/A||1970|
|Frederic Hilke||Investor Relations Officer||N/A||N/A||N/A|
|Dr. Noel Thomas Doheny||Chief Exec. Officer of Epigenomics Inc.||N/A||N/A||N/A|
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.
Epigenomics AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.